Clínica Baviera, S.A. (BME:CBAV)
Spain
· Delayed Price · Currency is EUR 53.40
+0.40 (0.75%)
Apr 28, 2026, 5:35 PM CET
Clínica Baviera Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 304.91 | 265.72 | 227.07 | 198.45 | 173.25 | Upgrade
|
| Revenue Growth (YoY) | 14.75% | 17.02% | 14.42% | 14.55% | 41.28% | Upgrade
|
| Cost of Revenue | 153.93 | 133.18 | 115.1 | 96.55 | 84.05 | Upgrade
|
| Gross Profit | 150.98 | 132.54 | 111.97 | 101.9 | 89.2 | Upgrade
|
| Selling, General & Admin | 17.78 | 13.93 | 12.09 | 11.69 | 9.87 | Upgrade
|
| Amortization of Goodwill & Intangibles | 23.9 | 20.88 | - | 15 | - | Upgrade
|
| Other Operating Expenses | 48.67 | 42.08 | 32.86 | 33.25 | 25.77 | Upgrade
|
| Operating Expenses | 90.34 | 76.89 | 61.93 | 59.94 | 49.73 | Upgrade
|
| Operating Income | 60.64 | 55.65 | 50.04 | 41.96 | 39.46 | Upgrade
|
| Interest Expense | -2.28 | -1.22 | -0.57 | -0.42 | -0.46 | Upgrade
|
| Interest & Investment Income | 1.52 | 0.3 | 0.15 | 0.07 | 0 | Upgrade
|
| Earnings From Equity Investments | 0.04 | -0.02 | -0.01 | -0.06 | -0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.08 | 0.04 | 0.01 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.07 | -0.4 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | 59.84 | 54.74 | 49.68 | 41.15 | 38.93 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.37 | 1.22 | - | - | - | Upgrade
|
| Asset Writedown | -0.1 | 0.03 | -0.03 | -0.47 | -0.03 | Upgrade
|
| Pretax Income | 60.11 | 55.99 | 49.65 | 40.68 | 38.9 | Upgrade
|
| Income Tax Expense | 17.18 | 14.86 | 12.92 | 10.53 | 10.97 | Upgrade
|
| Earnings From Continuing Operations | 42.94 | 41.14 | 36.73 | 30.15 | 27.93 | Upgrade
|
| Minority Interest in Earnings | -0.87 | -0.93 | -0.76 | -0.63 | -0.54 | Upgrade
|
| Net Income | 42.06 | 40.21 | 35.97 | 29.52 | 27.39 | Upgrade
|
| Net Income to Common | 42.06 | 40.21 | 35.97 | 29.52 | 27.39 | Upgrade
|
| Net Income Growth | 4.62% | 11.77% | 21.86% | 7.77% | 96.46% | Upgrade
|
| Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Change (YoY) | 0.08% | -1.85% | - | - | 0.01% | Upgrade
|
| EPS (Basic) | 2.63 | 2.51 | 2.21 | 1.81 | 1.68 | Upgrade
|
| EPS (Diluted) | 2.63 | 2.51 | 2.21 | 1.81 | 1.68 | Upgrade
|
| EPS Growth | 4.54% | 13.88% | 21.86% | 7.77% | 96.43% | Upgrade
|
| Free Cash Flow | 46.83 | 36 | 35.13 | 39.35 | 36.28 | Upgrade
|
| Free Cash Flow Per Share | 2.92 | 2.25 | 2.15 | 2.41 | 2.23 | Upgrade
|
| Dividend Per Share | 1.570 | 1.570 | 1.570 | 1.300 | 1.030 | Upgrade
|
| Dividend Growth | - | - | 20.77% | 26.21% | 86.59% | Upgrade
|
| Gross Margin | 49.52% | 49.88% | 49.31% | 51.35% | 51.49% | Upgrade
|
| Operating Margin | 19.89% | 20.94% | 22.04% | 21.14% | 22.78% | Upgrade
|
| Profit Margin | 13.79% | 15.13% | 15.84% | 14.88% | 15.81% | Upgrade
|
| Free Cash Flow Margin | 15.36% | 13.55% | 15.47% | 19.83% | 20.94% | Upgrade
|
| EBITDA | 82.77 | 75.63 | 66.5 | 56.76 | 53.35 | Upgrade
|
| EBITDA Margin | 27.15% | 28.46% | 29.29% | 28.60% | 30.80% | Upgrade
|
| D&A For EBITDA | 22.13 | 19.98 | 16.46 | 14.8 | 13.89 | Upgrade
|
| EBIT | 60.64 | 55.65 | 50.04 | 41.96 | 39.46 | Upgrade
|
| EBIT Margin | 19.89% | 20.94% | 22.04% | 21.14% | 22.78% | Upgrade
|
| Effective Tax Rate | 28.57% | 26.53% | 26.02% | 25.89% | 28.19% | Upgrade
|
| Advertising Expenses | 15.09 | 12.14 | 10.31 | 9.86 | 8.42 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.